<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02183428</url>
  </required_header>
  <id_info>
    <org_study_id>1218.30</org_study_id>
    <nct_id>NCT02183428</nct_id>
  </id_info>
  <brief_title>Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers</brief_title>
  <official_title>Relative Bioavailability of BI 1356 and Glyburide After Concomitant Administration of Multiple Oral Doses of BI 1356 5 mg Once Daily and a Single Oral Dose of Glyburide 1.75 mg Compared With the Bioavailability of BI 1356 and Glyburide After Each Treatment Given Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Two-way Crossover Study of Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the effect of multiple doses BI 1356 given&#xD;
      once daily in the estimated highest therapeutic dose of 5 mg until steady state on the&#xD;
      pharmacokinetics, safety, and tolerability of a single oral conventional therapeutic dose of&#xD;
      1.75 mg glyburide. In addition, the effect of glyburide as a single oral dose of 1.75 mg&#xD;
      being a conventional therapeutic dose on the multiple dose pharmacokinetics of BI 1356 was&#xD;
      investigated. Pharmacokinetic profiles of glyburide were determined when given alone or in&#xD;
      combination with BI 1356. Pharmacokinetic profiles of BI 1356 and its inactive metabolite CD&#xD;
      1750 were determined at steady state of BI 1356 when given alone or in combination with&#xD;
      glyburide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of glyburide in plasma) for several time points</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of glyburide in plasma) for several time points</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 1356</measure>
    <time_frame>up to 48 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 1356</measure>
    <time_frame>up to 48 h after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma) for several time points</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of the analyte in the body after po administration) for several time points</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in the plasma after extravascular administration) for several time points</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) for several time points</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>Day 1 of treatment B, day 3 of treatment B and C</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the concentration-time curve of the analyte in plasma) for several time points</measure>
    <time_frame>up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of CD 1750</measure>
    <time_frame>up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1356</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence AB_C or C_AB&#xD;
Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by&#xD;
Treatment B: 1 day of combined treatment of BI1356 and glyburide&#xD;
Treatment C: 1 day of treatment with glyburide alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyburide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment sequence AB_C or C_AB&#xD;
Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by&#xD;
Treatment B: 1 day of combined treatment of BI1356 and glyburide&#xD;
Treatment C: 1 day of treatment with glyburide alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356</intervention_name>
    <arm_group_label>BI 1356</arm_group_label>
    <arm_group_label>Glyburide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <arm_group_label>BI 1356</arm_group_label>
    <arm_group_label>Glyburide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356 + Glyburide</intervention_name>
    <arm_group_label>BI 1356</arm_group_label>
    <arm_group_label>Glyburide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy females and males according to the following criteria: Based upon a complete&#xD;
             medical history, including the physical examination, vital signs (Blood Pressure (BP),&#xD;
             Pulse Rate (PR)), 12-lead (ECG) Electrocardiogram, clinical laboratory tests&#xD;
&#xD;
          -  Age ≥18 and Age ≤55 years&#xD;
&#xD;
          -  BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination (including BP, PR and ECG) deviating from&#xD;
             normal and of clinical relevance&#xD;
&#xD;
          -  Any evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract (except appendectomy)&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy or hypersensitivity (including allergy to drug or its&#xD;
             excipients)&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less&#xD;
             than 10 half-lives of the respective drug prior to administration or during the trial&#xD;
&#xD;
          -  Use of drugs which might reasonably influence the results of the trial or that prolong&#xD;
             the QT/QTc interval based on the knowledge at the time of protocol preparation within&#xD;
             10 days prior to administration or during the trial, including herbal products&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within two months prior to&#xD;
             administration or during the trial&#xD;
&#xD;
          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)&#xD;
&#xD;
          -  Inability to refrain from smoking on trial days&#xD;
&#xD;
          -  Alcohol abuse (more than 60 g/day)&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Blood donation (more than 100 mL within four weeks prior to administration or during&#xD;
             the trial)&#xD;
&#xD;
          -  Excessive physical activities (within one week prior to administration or during the&#xD;
             trial)&#xD;
&#xD;
          -  Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
          -  Inability to comply with dietary regimen of trial site&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTc interval &gt;450 ms)&#xD;
&#xD;
          -  A history of additional risk factors for torsade de pointes (e.g., heart failure,&#xD;
             hypokalaemia, family history of Long QT Syndrome)&#xD;
&#xD;
          -  Galactose intolerance&#xD;
&#xD;
          -  Lactase deficiency&#xD;
&#xD;
          -  Glucose-galactose-malabsorption&#xD;
&#xD;
        For all female subjects:&#xD;
&#xD;
          -  Pregnancy or planning to become pregnant within 2 months of study completion&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  No adequate contraception e.g. , sterilisation, IUD (intrauterine device), have not&#xD;
             been using a barrier method of contraception for at least 3 months prior to&#xD;
             participation in the study&#xD;
&#xD;
          -  Not willing or unable to use a reliable method of barrier contraception (such as&#xD;
             diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and&#xD;
             up to 2 months after completion/termination of the trial&#xD;
&#xD;
          -  Partner is unwilling to use condoms&#xD;
&#xD;
          -  Lactation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.30_U09-1247-01.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02183428
org study id: 1218.30
nct id: NCT02183428
lead sponsor: 
The objective of this study was to investigate the effect of multiple doses BI 1356 given
      once daily in the estimated highest therapeutic dose of 5 mg until steady state on the
      pharmacokinetics, safety, and tolerability of a single oral conventional therapeutic dose of
      1.75 mg glyburide. In addition, the effect of glyburide as a single oral dose of 1.75 mg
      being a conventional therapeutic dose on the multiple dose pharmacokinetics of BI 1356 was
      investigated. Pharmacokinetic profiles of glyburide were determined when given alone or in
      combination with BI 1356. Pharmacokinetic profiles of BI 1356 and its inactive metabolite CD
      1750 were determined at steady state of BI 1356 when given alone or in combination with
      glyburide.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: AUC0-infinity (area under the concentration-time curve of glyburide in plasma) for several time points
time frame: up to 48 hours after drug administration
measure: Cmax (maximum measured concentration of glyburide in plasma) for several time points
time frame: up to 48 hours after drug administration
measure: AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 1356
time frame: up to 48 h after drug administration
measure: Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 1356
time frame: up to 48 h after drug administration
measure: tmax (time from dosing to the maximum concentration of the analyte in plasma) for several time points
time frame: up to 48 hours after drug administration
measure: λz (terminal rate constant in plasma)
time frame: up to 48 hours after drug administration
measure: t1/2 (terminal half-life of the analyte in plasma)
time frame: up to 48 hours after drug administration
measure: MRTpo (mean residence time of the analyte in the body after po administration) for several time points
time frame: up to 48 hours after drug administration
measure: CL/F (apparent clearance of the analyte in the plasma after extravascular administration) for several time points
time frame: up to 48 hours after drug administration
measure: Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) for several time points
time frame: up to 48 hours after drug administration
measure: Number of patients with adverse events
time frame: up to 11 weeks
measure: Assessment of tolerability by investigator on a 4-point scale
time frame: Day 1 of treatment B, day 3 of treatment B and C
measure: AUC (area under the concentration-time curve of the analyte in plasma) for several time points
time frame: up to 48 h after drug administration
measure: Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of CD 1750
time frame: up to 48 h after drug administration
arm group label: BI 1356
arm group type: Experimental
description: Treatment sequence AB_C or C_AB
Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by
Treatment B: 1 day of combined treatment of BI1356 and glyburide
Treatment C: 1 day of treatment with glyburide alone
arm group label: Glyburide
arm group type: Active Comparator
description: Treatment sequence AB_C or C_AB
Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by
Treatment B: 1 day of combined treatment of BI1356 and glyburide
Treatment C: 1 day of treatment with glyburide alone
intervention type: Drug
intervention name: BI 1356
arm group label: BI 1356
arm group label: Glyburide
intervention type: Drug
intervention name: Glyburide
arm group label: BI 1356
arm group label: Glyburide
intervention type: Drug
intervention name: BI 1356 + Glyburide
arm group label: BI 1356
arm group label: Glyburide
criteria: 
gender: All
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
url: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.30_U09-1247-01.pdf
description: Related Info
responsible party type: Sponsor
mesh term: Glyburide
mesh term: Linagliptin